MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
10.27
-0.87 (-7.81%)
May 13, 2025, 4:00 PM - Market closed
MBX Biosciences Employees
MBX Biosciences had 43 employees as of December 31, 2024. The number of employees increased by 16 or 59.26% compared to the previous year.
Employees
43
Change (1Y)
16
Growth (1Y)
59.26%
Revenue / Employee
n/a
Profits / Employee
-$1,708,488
Market Cap
343.27M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43 | 16 | 59.26% |
Dec 31, 2023 | 27 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MBX News
- 1 day ago - MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 21 days ago - MBX Biosciences to Participate in Citizens and RBC May Investor Conferences - GlobeNewsWire
- 6 weeks ago - MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 months ago - MBX Biosciences Announces Additions to Leadership Team - GlobeNewsWire
- 2 months ago - MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism - GlobeNewsWire
- 3 months ago - MBX Biosciences to Participate in March Investor Conferences - GlobeNewsWire
- 4 months ago - MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia - GlobeNewsWire